Latham & Watkins Advises Revolution Medicines in its US$230 Million Public Offering

Revolution Medicines, Inc. (Nasdaq: RVMD), has announced the pricing of its underwritten public offering of 11,500,000 shares of common stock at a public offering price of US$20 per share, before underwriting discounts and commissions. All of the shares of common stock are being offered by Revolution Medicines, which also has granted the underwriters a 30-day option to purchase up to an additional 1,725,000 shares of common stock at the public offering price, less underwriting discounts, and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Revolution Medicines, are expected to be US$230 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on July 22, 2022, subject to customary closing conditions.

Latham & Watkins LLP represents Revolution Medicines in the offering with a corporate team led by Bay Area partners Mark Roeder and John Williams, with associates Zuzanna Gruca, Taimi Jacobson, and Joshua Landis. Advice has also been provided on regulatory matters by Washington, D.C. partners John Manthei and Elizabeth Richards, Bay Area partner Heather Deixler, Bay Area counsel Betty Pang, Washington, D.C. associate Nathan Beaton, and Los Angeles associate Leia Gu; on tax matters by Bay Area partner Grace Lee and associate Derek Gumm; on benefits and compensation matters by Bay Area partner James Metz; and on intellectual property matters by Bay Area partner Christopher Hazuka and San Diego associate Kristina Funahashi.